Baird $ARCT among most undervalued mRNA therapeutics firms in spite of multiple value- added partnerships. Relative to peer mRNA therapeutics companies $BNTX $MRNA $TBIO $JNJ ARCT remains substantially undervalued despite numerous validating partnerships https://t.co/rD0UFBZTVa